
Pharmacally
Migraine
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Migraine
Mergers & AcquisitionsBrise Reports Milestone Progress in $757M AbbVie Migraine DealBrise Pharmaceuticals has achieved several near-term milestones under its licensing agreement with AbbVie for two preclinical migraine programmes.Fact-Checked
Clinical TrialsLundbeck’s PACAP Inhibitor Bocunebart Meets Endpoint in MigraineLundbeck reported positive Phase IIb results for bocunebart in migraine prevention. The PACAP-targeting antibody significantly reduced monthly migraine days versus placebo, with stronger effects in patients with chronic…Fact-Checked
New Drug ApprovalVyepti Wins South Korea Approval for Adult MigraineH. Lundbeck A/S has secured marketing authorization from South Korea’s Ministry of Food and Drug Safety for Vyepti (eptinezumab) in adults with migraine.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.